Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5227 - Outcome of Non-metastatic Male Breast Cancer: 222 patients

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Ulku Yalcintas Arslan

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

U.Y. Arslan1, F. Aslan2, M. Ayhan3, N. Akdeniz4, G. Tahtacı5, H. Yeşil Çınkır6, M. inanc7, G.I. Imamoglu8, N. Alkış1, N. Turan3, M.A. Kaplan9, N.Y. ozdemir10, O.B. Cakmak Oksuzoglu1

Author affiliations

  • 1 Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Onkoloji Training and Research Hospital, 06200 - Ankara/TR
  • 2 Medical Oncology, Medikal Park Hospital, Ankara/TR
  • 3 Medical Oncology, Kartal Lütfi Kırdar Training and Research Hospital, İstanbul/TR
  • 4 Department Of Oncology, Dicle University Medical Facultiy, 21080 - Diyarbakir/TR
  • 5 Medical Oncology, Gazi University Faculty of Medicine, Ankara/TR
  • 6 Department Of Medical Oncology, Gaziantep University Medical Faculty, 27100 - Gaziantep/TR
  • 7 Medical Oncology, School of Medicine Erciyes University, 38900 - kayseri/TR
  • 8 Medical Oncology, Diskapi Yildirim Beyazit Teaching and Research Hospital, 6110 - Ankara/TR
  • 9 Department Of Oncology, Dicle University Medical Facultiy, 38000 - Diyarbakır/türkiye/TR
  • 10 Medical Oncology, Gazi University Faculty of Medicine, 01000 - ankara/TR
More

Resources

Abstract 5227

Background

There are limited data for Male breast carcinoma(MBC) in the era of adjuvant taxanes and trastuzumab. We have previously reported outcome of non-metastatic 113 patients(pts) with MBC. We aimed to evaluate outcome of the changing adjuvant systemic treatment practices and survival in operable MBC.

Methods

The medical records of 261 MBC pts followed between 1986-2018 at 8 cancer center were reviewed retrospectively. 222 patients had non-metastatic MBC at the time of diagnosis were included in current study.

Results

Median age was 61(29-91) years. Median follow-up 55(1-275)months(mths). %91 of the pts had invasive ductal carcinoma. Also, 30.6% had T3-4 tumors. About half of study group had axillary lymph node-positive tumors. The proportion of positivity of ER, PgR and HER2 status were % 82.5, 73.1 and %18.4. Ten pts had TN MBC. 55 of pts had at least one comorbid chronic illness. 83.9 % of pts had modified radical mastectomy(MRM). 79.9% of pts received adjuvant radiotherapy. Adjuvan hormonotherapy were advised for %78.8, whereas adjuvant chemotherapy(CT) for 71.2 % of the pts(CMF 10.6%, adjuvant trastuzumab %7.5 and antracycline and/or taxane based 81.9% ). 9 HER2-positive pts had no adjuvant CT. Locoregional and/or distant recurrence rate was 36.9%. 77 (34.5%) pts died during follow-up. 52 of them died from metastatic breast cancer. 5-year disease-free survival(DFS) was found to be 66.6 % whereas overall survival(OS) was 73.5 %. Patients with stage I/II tumor were significantly longer DFS as compared to pts had stage III MBC( median not reached vs 78 mths, P<.001). Also, the latter group of pts had worse OS than the first group ( median 103 vs 153 mths, P=.030). Median DFS for pts had MRM was significantly better than patients had limited surgery (one-third of those pts had no axillary dissection)(118 vs 57 mths, P=.002). Two HER2-positive pts treated with adjuvant trastuzumab containing regimen had breast cancer recurrence(n = 11) and alive whereas 9 of 19 pts treated other chemotherapy regimen (All but 2 anthracycline and/or taxane based) had experienced the disease relapse and 7 of them died from MBC.

Conclusions

Although the adjuvant use of anthracyclines /taxanes and trastuzumab for MBC have increased in the last 10 years, stage at diagnosis is still important prognostic factor for survival in MBC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings